ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of biotechnology, companies often face unique challenges, particularly when it comes to navigating public markets and securing investment.

Tim McCarthy, CEO of ImmuPharma, shares his insights on the current state of the biotech industry, the innovations at ImmuPharma, and the importance of effective communication with investors. Join us as we delve into ImmuPharma's transformative journey, the significance of its groundbreaking research, and what the future holds for the company.

Tim opens the discussion by acknowledging the struggles that biotech firms, especially those listed on the London market, often encounter. The UK and Europe lack the depth of capital markets that are available in the US, making it more challenging for biotech companies to thrive. Tim reflects on his extensive experience in the sector. He highlights that the primary issue is not just access to capital but also the understanding of what biotech companies bring to the table.

“We don’t have the same appreciation for the intellectual resources that biotech brings,” he notes. This lack of recognition has led to many small biotechs leaving the market, unable to secure the funding they desperately need. Tim emphasizes that for many biotech companies, the public market is critical for raising capital, particularly during the development phases when they are not generating revenue.

One of the key elements for biotech companies like ImmuPharma is maintaining a steady flow of substantial news. Tim explains that news flow is the lifeblood of biotech companies. It’s not enough to release press releases just to remain visible; these updates need to convey meaningful progress and be understandable to a broader audience.

“The majority of investors out there are not scientists,” he points out, highlighting the need for clarity in communicating complex scientific advancements. Tim believes that if investors better understood the technology and breakthroughs, it could lead to improved valuations and liquidity for biotech companies.

https://www.share-talk.com/transforming-biotech-insights-from-tim-mccarthy-ceo-of-immupharma/